Drug intelligence / Profile preview

DIA03-N2BS

Development stage: Preclinical
Lead developer: Dianosic
Modality: Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intranasal

Overview

DIA03-N2BS is an exploratory preclinical-stage intranasal drug delivery platform being developed by Dianosic for the treatment of central nervous system disorders, specifically refractory (resistant) schizophrenia. The program utilizes Dianosic's proprietary Nose-to-Brain (N2B) delivery technology, which leverages drug-eluting, long-acting, resorbable polymer inserts (the DIAXX platform) to deliver therapeutic agents directly to the brain via the nasal cavity. This approach aims to bypass the blood-brain barrier, maximize treatment adherence, and minimize systemic side effects associated with traditional oral or systemic therapies.

Other names: DIA03-NTB SolutionDIA-03-NTB SolutionDIA 03-NTB SolutionNose-to-brain intranasal delivery program (NTB)

Beyond the preview

Go deeper on DIA03-N2BS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DIA03-N2BS.